Sponsors (6)
This is not an official government website.
Copyright © 2026 PLEJ LC. All rights reserved.
Introduced February 27, 2025 by Marilyn Strickland · Last progress February 27, 2025
Establishes a coordinated federal effort to improve research, detection, treatment, workforce training, and public education for rare diseases that disproportionately affect minority and Tribal communities. It creates new grant programs, training and incentive programs for health professionals, and requires reviews and reports from HHS agencies (NIH, CDC, FDA, Medicare) to identify barriers and data gaps and to guide future work. The measure funds or authorizes grants and programs across multiple agencies: Tribal epidemiology center grants and Tribal/Urban Indian clinic support; NIH-led coordination, planning, and expanded research; CDC data, outreach, and public awareness; HRSA grants, mentoring, scholarships, and loan repayment tied to serving populations with rare diseases; and FDA and Medicare reviews focused on clinical-trial data, racial inclusion, and telehealth access for rare disease treatment. Many provisions authorize activities but do not specify total appropriation amounts; several reports and implementation plans are required within 180 days to 2 years of enactment.
The bill directs substantial federal attention toward improving rare-disease research, workforce capacity, data, and outreach for racial, ethnic, and Tribal communities—potentially improving diagnosis and care—but relies heavily on discretionary funding, reports, and implementation choices that could delay benefits, raise costs, and require trade-offs with other health priorities.
Racial and ethnic minority populations (including Native American and Alaska Native communities) will receive targeted research, surveillance, and programmatic attention that can improve diagnosis, treatment, and care for rare diseases.
Students, clinicians, and researchers gain expanded training, scholarships, loan-repayment, mentoring, and workforce-development programs that should increase clinician capacity and research expertise for rare diseases (helping underserved, rural, and Tribal areas).
Improved federal data collection, lists and regular reporting to Congress will give policymakers and researchers clearer information to target funding and programs for rare diseases affecting minority populations.
The bill likely increases federal spending (and potential taxpayer costs) for new grants, research, training, and programs, while many sections leave funding discretionary or unspecified.
Many provisions primarily require reviews, reports, or program authorizations without guaranteed appropriations, so benefits may be delayed, limited, or never fully implemented.
If Congress does not provide new funding, the initiative could shift existing NIH/HHS resources away from other research and public‑health priorities, reducing support for non-rare conditions.